FindTrial
Sign In

Coronary atherosclerotic heart disease column and database research

The clinical efficacy of Kuanxiong aerosol pectoris in the treatment of coronary heart disease angina and its influence on related inflammatory indexes and platelets: a single center, retrospective, cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053344
Enrollment
Unknown
Registered
2021-11-19
Start date
2021-07-31
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Kuanxiong aerosol pectoris group:No
Control group:No

Sponsors

Wuhan Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnosis of coronary heart disease; 2. Aged 18-90 years; 3. Clinical examination, the basics of diagnosis and treatment is basically complete; 4. Patients recently repeated chest pain discomfort; 5. Good compliance, patients and their families understand and support this study.

Exclusion criteria

Exclusion criteria: 1. Complete liver and kidney function serious damage, mental abnormal patients and other serious diseases; 2. There is adverse reactor using wide chest aerosol; 3. Pregnancy or lactating female; 4. Participate in other clinical experiments at the same time.

Design outcomes

Primary

MeasureTime frame
Blood indicator;Angina pectoris;—

Countries

China

Contacts

Public ContactLi Dongsheng

Wuhan Third Hospital

dongshengli196809@163.com+86 18872288277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026